STOCK TITAN
  1. Home
  2. Sec-filings
  3. TECX
  4. [Form 4] Tectonic Therapeutic, Inc. Insider Trading Activity

Director at Tectonic Therapeutic (TECX) granted 10,200 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. director Praveen P. Tipirneni received a grant of stock options covering 10,200 shares of common stock at an exercise price of $28.56 per share. These options were awarded as a compensation grant, not an open-market purchase or sale.

The options vest in full on the earliest of June 9, 2027, the company’s 2027 annual meeting of stockholders, or a qualifying change in control, as long as the director continues providing service through that date. After this grant, the reported derivative holdings in this award total 10,200 options.

Positive

  • None.

Negative

  • None.
Insider Tipirneni Praveen P.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 10,200 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 10,200 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 10,200 options Stock Option (Right to Buy) grant to director
Exercise price $28.56 per share Exercise price of granted stock options
Underlying shares 10,200 shares Common stock underlying the options
Expiration date 2036-06-08 Option expiration for this grant
Holdings after grant 10,200 derivative securities Total options in this award after transaction
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Change in Control financial
"or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan)"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2024 Equity Incentive Plan financial
"as defined in the Issuer's 2024 Equity Incentive Plan"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tipirneni Praveen P.
(Last)(First)(Middle)
C/O TECTONIC THERAPEUTIC, INC.
490 ARSENAL WAY, SUITE 200
(Street)
WATERTOWN MASSACHUSETTS 02472
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$28.5606/09/2026A10,200 (1)06/08/2036Common Stock10,200$010,200D
Explanation of Responses:
1. The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.
/s/ Daniel Lochner, Attorney-in-Fact06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did TECX report in this Form 4?

Tectonic Therapeutic reported a director compensation grant of stock options for 10,200 shares. The options give the right to buy common stock at a fixed exercise price and do not involve any open-market buying or selling of shares.

How many Tectonic Therapeutic (TECX) options were granted to the director?

The director was granted stock options covering 10,200 shares of Tectonic Therapeutic common stock. This entire amount is reflected as derivative holdings following the transaction, indicating a single, newly awarded option grant in this filing.

What is the exercise price of the TECX stock options granted?

The granted stock options have an exercise price of $28.56 per share. This is the price at which the director can purchase Tectonic Therapeutic common stock in the future once the options vest and become exercisable.

When do the TECX director’s stock options vest?

The options vest in full on the earliest of June 9, 2027, the 2027 annual stockholders’ meeting, or a qualifying change in control. Vesting requires the director to continue providing service to Tectonic Therapeutic through the applicable vesting date.

Is this TECX Form 4 an open-market purchase or sale of shares?

No. The Form 4 reports a grant of stock options as compensation, not an open-market trade. The transaction is classified as a derivative award acquisition, with no shares bought or sold on the public market in this filing.